JP2012524731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524731A5 JP2012524731A5 JP2012506333A JP2012506333A JP2012524731A5 JP 2012524731 A5 JP2012524731 A5 JP 2012524731A5 JP 2012506333 A JP2012506333 A JP 2012506333A JP 2012506333 A JP2012506333 A JP 2012506333A JP 2012524731 A5 JP2012524731 A5 JP 2012524731A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound according
- triazin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,3-oxazol-2-yl Chemical group 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 49
- 230000003287 optical Effects 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000011780 sodium chloride Substances 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229920000388 Polyphosphate Polymers 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 235000011178 triphosphate Nutrition 0.000 claims description 12
- 239000001226 triphosphate Substances 0.000 claims description 12
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 229910052736 halogen Chemical group 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims description 8
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 230000002113 chemopreventative Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000001613 neoplastic Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000002062 proliferating Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims description 2
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 claims description 2
- 229940046844 Aromatase inhibitors Drugs 0.000 claims description 2
- 102100000899 GNRH1 Human genes 0.000 claims description 2
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims description 2
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 229930013930 alkaloids Natural products 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
- 230000003042 antagnostic Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000002280 anti-androgenic Effects 0.000 claims description 2
- 230000001772 anti-angiogenic Effects 0.000 claims description 2
- 239000000051 antiandrogen Substances 0.000 claims description 2
- 239000003080 antimitotic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 0 *C1(C([n]2c3ncnc(N)c3c(*)c2)OC(CO)C1O)O Chemical compound *C1(C([n]2c3ncnc(N)c3c(*)c2)OC(CO)C1O)O 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17165609P | 2009-04-22 | 2009-04-22 | |
US61/171,656 | 2009-04-22 | ||
PCT/CZ2010/000050 WO2010121576A2 (en) | 2009-04-22 | 2010-04-19 | Novel 7-deazapurine nucleosides for therapeutic uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014213410A Division JP6087889B2 (ja) | 2009-04-22 | 2014-10-20 | 治療的使用のための新規7−デアザプリンヌクレオシド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012524731A JP2012524731A (ja) | 2012-10-18 |
JP2012524731A5 true JP2012524731A5 (ru) | 2013-05-30 |
JP5721275B2 JP5721275B2 (ja) | 2015-05-20 |
Family
ID=42768153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012506333A Active JP5721275B2 (ja) | 2009-04-22 | 2010-04-19 | 治療的使用のための新規7−デアザプリンヌクレオシド |
JP2014213410A Active JP6087889B2 (ja) | 2009-04-22 | 2014-10-20 | 治療的使用のための新規7−デアザプリンヌクレオシド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014213410A Active JP6087889B2 (ja) | 2009-04-22 | 2014-10-20 | 治療的使用のための新規7−デアザプリンヌクレオシド |
Country Status (16)
Country | Link |
---|---|
US (3) | US9321800B2 (ru) |
EP (1) | EP2421879B1 (ru) |
JP (2) | JP5721275B2 (ru) |
CN (2) | CN104497084B (ru) |
AU (3) | AU2010238985B2 (ru) |
CA (2) | CA2759131C (ru) |
DK (1) | DK2421879T3 (ru) |
ES (1) | ES2437917T3 (ru) |
HK (2) | HK1166325A1 (ru) |
HR (1) | HRP20131021T1 (ru) |
MX (1) | MX2011011160A (ru) |
NZ (2) | NZ596301A (ru) |
PL (1) | PL2421879T3 (ru) |
PT (1) | PT2421879E (ru) |
SI (1) | SI2421879T1 (ru) |
WO (1) | WO2010121576A2 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2421879B1 (en) * | 2009-04-22 | 2013-09-04 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Novel 7-deazapurine nucleosides for therapeutic uses |
MX2012007026A (es) * | 2009-12-18 | 2013-03-18 | Joslin Diabetes Center Inc | Compuestos que promueven la replicacion de celula beta y metodos de su uso. |
CN102319254B (zh) * | 2011-07-20 | 2013-06-19 | 上海交通大学 | 5-碘代杀菌核素在制备抗肿瘤药物中的应用 |
CZ305466B6 (cs) * | 2013-11-04 | 2015-10-14 | Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. | Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití |
US10221181B2 (en) | 2014-11-14 | 2019-03-05 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3478701B1 (en) | 2016-06-29 | 2022-08-10 | Ustav organicke chemie a biochemie AV CR, v.v.i. | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use |
CZ307334B6 (cs) | 2016-08-02 | 2018-06-13 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
US11072628B2 (en) | 2017-10-19 | 2021-07-27 | Universiteit Gent | Nucleoside analogues for the treatment of parasitic infections |
JP7061195B2 (ja) * | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CZ308104B6 (cs) | 2018-03-12 | 2020-01-08 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. | Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
CA3108388A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
BR112021025443A2 (pt) * | 2019-06-18 | 2022-02-01 | Taiho Pharmaceutical Co Ltd | Compostos de éster fosfato com esqueleto de pirrolopirimidina ou sal farmaceuticamente aceitável do mesmo, agentes antitumorais e composições farmacêuticas compreendendo os ditos compostos, bem como usos e usos terapêuticos dos mesmos |
WO2021164848A1 (en) * | 2020-02-17 | 2021-08-26 | Katholieke Universiteit Leuven | Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments |
EP4300796A1 (en) | 2021-02-26 | 2024-01-03 | Hitachi Industrial Products, Ltd. | Dynamo-electric machine |
CA3233416A1 (en) | 2021-09-28 | 2023-04-06 | Universiteit Antwerpen | Nucleoside analogues for the treatment of parasitic infections |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
AU2002353165A1 (en) * | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
US20040157892A1 (en) | 2003-02-12 | 2004-08-12 | Crompton Co./Cie | Pesticidal fluoroethyl pyrazoles |
US7202223B2 (en) * | 2003-10-27 | 2007-04-10 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
CA2543116A1 (en) * | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
US7157434B2 (en) * | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
WO2006033709A2 (en) * | 2004-07-29 | 2006-03-30 | Metabasis Therapeutics, Inc. | Novel nucleoside derivatives |
HUE030767T2 (en) * | 2008-01-18 | 2017-05-29 | Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic | New, cytostatic 7-deazapurine nucleosides |
MX2010014501A (es) * | 2008-06-23 | 2011-02-25 | Janssen Pharmaceutica Nv | Antagonistas de piperidil acrilamida de receptor 2 de citocina quimioatrayente. |
GB0815968D0 (en) * | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
EP2421879B1 (en) * | 2009-04-22 | 2013-09-04 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Novel 7-deazapurine nucleosides for therapeutic uses |
-
2010
- 2010-04-19 EP EP10734433.5A patent/EP2421879B1/en active Active
- 2010-04-19 DK DK10734433.5T patent/DK2421879T3/da active
- 2010-04-19 JP JP2012506333A patent/JP5721275B2/ja active Active
- 2010-04-19 NZ NZ596301A patent/NZ596301A/en unknown
- 2010-04-19 CA CA2759131A patent/CA2759131C/en active Active
- 2010-04-19 MX MX2011011160A patent/MX2011011160A/es active IP Right Grant
- 2010-04-19 SI SI201030450T patent/SI2421879T1/sl unknown
- 2010-04-19 US US14/394,262 patent/US9321800B2/en active Active
- 2010-04-19 CN CN201410643709.3A patent/CN104497084B/zh active Active
- 2010-04-19 CA CA2966647A patent/CA2966647A1/en not_active Abandoned
- 2010-04-19 AU AU2010238985A patent/AU2010238985B2/en active Active
- 2010-04-19 ES ES10734433.5T patent/ES2437917T3/es active Active
- 2010-04-19 WO PCT/CZ2010/000050 patent/WO2010121576A2/en active Application Filing
- 2010-04-19 CN CN201080027802.1A patent/CN102459300B/zh active Active
- 2010-04-19 PL PL10734433T patent/PL2421879T3/pl unknown
- 2010-04-19 NZ NZ700583A patent/NZ700583A/en active IP Right Revival
- 2010-04-19 PT PT107344335T patent/PT2421879E/pt unknown
-
2012
- 2012-07-18 HK HK12107027.8A patent/HK1166325A1/xx unknown
-
2013
- 2013-10-28 HR HRP20131021AT patent/HRP20131021T1/hr unknown
-
2014
- 2014-10-20 JP JP2014213410A patent/JP6087889B2/ja active Active
-
2015
- 2015-07-22 AU AU2015205885A patent/AU2015205885B2/en active Active
- 2015-10-08 HK HK15109842.4A patent/HK1209129A1/xx unknown
-
2016
- 2016-03-17 US US15/073,502 patent/US9624257B2/en active Active
-
2017
- 2017-03-08 US US15/453,702 patent/US10294262B2/en active Active
- 2017-06-19 AU AU2017204148A patent/AU2017204148B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012524731A5 (ru) | ||
CN105683166B (zh) | 取代的嘧啶Bmi-1抑制剂 | |
JP2017528498A5 (ru) | ||
JP2017528524A5 (ru) | ||
JP2007529421A5 (ru) | ||
JP2008535902A5 (ru) | ||
JP2011509949A5 (ru) | ||
JP2001522842A5 (ru) | ||
JP2014518266A5 (ru) | ||
JP2016513737A5 (ru) | ||
JP2019501197A5 (ja) | 腫瘍を処置するための抗her2組み合わせ | |
JP2015500887A5 (ru) | ||
JP2013501731A5 (ru) | ||
JP2009538897A5 (ru) | ||
JP2020506951A5 (ru) | ||
JP2006506443A5 (ru) | ||
JP2011526917A5 (ru) | ||
JP2014508804A5 (ru) | ||
CN109819649B (zh) | 氨基嘌呤化合物的固体形式及其使用方法 | |
US20220354842A1 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents | |
JP2014144962A5 (ru) | ||
JP2008528617A5 (ru) | ||
JP2017535600A5 (ru) | ||
SI3174881T1 (en) | (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases | |
JP2018525425A5 (ru) |